Innoviva, Inc. (INVA): Valuation
TTM figures as of June 30, 2026
Innoviva, Inc. trades at 4.2 times trailing earnings and a 12.69% free-cash-flow yield. On P/E that is higher than 33% of its own month-end history back to 2011. The Healthcare median P/E is 22.9.
Earnings yield 23.93%. Shareholder yield 3.54%. ROIC 15.0%. Piotroski F-score 5 of 9. Net cash $311.9M.
186 month-end valuation observations are on file, starting March 2011.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is INVA cheap versus its own history?
Innoviva, Inc. trades at 4.2 times trailing earnings and a 12.69% free-cash-flow yield. On P/E that is higher than 33% of its own month-end history back to 2011. The Healthcare median P/E is 22.9.
What is INVA's free-cash-flow yield?
Innoviva, Inc. currently yields 12.69% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.